BTAI News and Press, BioXcel Therapeutics Inc. From 02/09/24

A look at the top 10 most actives in the United States NanoString Technologies Inc. (NSTG) rose 121.6% to $0.2575 on volume of 398,287,485 shares Sunworks Inc. (SUNW) rose 116.6% to $0.11785 on volume of 366,627,028 shares Green Giant Inc. (GGE) rose 15.1% to $0.0426 on volume of 195,208,...

2024-02-09 12:50:35 ET More on Mid-day movers & stocks. BioXcel Therapeutics, Inc. (BTAI) Q3 2023 Earnings Call Transcript Sunworks files for Chapter 7 bankruptcy BioXcel slumps after Q3 pipeline update Seeking Alpha’s Quant Rating on BioXcel Thera...

2024-02-09 10:00:22 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...

2024-02-08 16:06:53 ET More on BioXcel Therapeutics BioXcel slumps after Q3 pipeline update Seeking Alpha’s Quant Rating on BioXcel Therapeutics Historical earnings data for BioXcel Therapeutics Read the full article on Seeking Alpha For furthe...

NEW HAVEN, Conn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it ha...

Human proof of concept portion of the trial expected to begin in H1 2024; led by Georgetown Lombardi Comprehensive Cancer Center BXCL701 in combination with checkpoint inhibitor in preclinical studies demonstrated encouraging results in pancreatic cancer Initial study data expec...

2024-02-05 08:31:42 ET Chenghe Acquisition  ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies  ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...

Aligns with Company’s strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer’s patients IGALMI™ market exclusivity further strengthened with receipt of issue notification for additional method of use patent (total...

2024-01-12 16:26:07 ET BioXcel Therapeutics ( NASDAQ: BTAI ) on Friday filed a prospectus related to the proposed resale of 69.63K common shares by the selling stockholders. This prospectus is not an offer to sell these securities. SEC Filing For further det...

Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential treatment for chronic use Dr. Sandra Comer to discuss BXCL501 as a potential treatment f...